Reuters logo
BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
November 9, 2017 / 10:15 PM / 8 days ago

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

Nov 9 (Reuters) - Dynavax Technologies Corp

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

* Dynavax Technologies Corp - ‍expects to commercially launch Heplisav-B in United States in Q1 of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below